Engineered Protein Inhibitors of SARS-CoV-2 Entry: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 6: Line 6:
SARS-CoV-2 better known as Covid-19 sent the world into a global pandemic due to its rapid [https://www.who.int/europe/emergencies/situations/covid-19 transmission and  infection]. In order to create a vaccine, it was essential to understand how SARS-CoV-2 infected us.  
SARS-CoV-2 better known as Covid-19 sent the world into a global pandemic due to its rapid [https://www.who.int/europe/emergencies/situations/covid-19 transmission and  infection]. In order to create a vaccine, it was essential to understand how SARS-CoV-2 infected us.  


The enzyme [https://en.wikipedia.org/wiki/Angiotensin-converting_enzyme angiotensin converting enzyme 2] <scene name='10/1077473/Ace2_monomer/1'>(ACE2)</scene> is attached to our cell membranes and then can be bound to a receptor binding domain <scene name='10/1077473/Ace2andrbd2/1'>(RBD)</scene> <ref name="Borkotoky">PMID:36562937</ref>. The virus, [https://en.wikipedia.org/wiki/SARS-CoV-2 SARS-CoV-2], enters our bodies containing a <scene name='10/1077473/Rbd_only/2'>spike protein</scene> protruding from the viral membrane. The RBD on the end of the spike protein <scene name='10/1076049/Ace2andrbd/1'>binds to ACE2</scene> giving SARS-CoV-2 the ability to enter our host cells <ref name="Jackson">PMID:34611326</ref>. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies, causing us to get sick. Figure 1 demonstrates the path SARS-CoV-2 takes to get into our cells. In order to create an effective vaccine, the pathway between the spike protein and the RBD needed to be interrupted <ref name=”Zhu”>PMID:36682464</ref>.
The enzyme [https://en.wikipedia.org/wiki/Angiotensin-converting_enzyme angiotensin converting enzyme 2] <scene name='10/1077473/Ace2_monomer/1'>(ACE2)</scene> is attached to our cell membranes and then can be bound to a receptor binding domain <scene name='10/1077473/Ace2andrbd2/1'>(RBD)</scene> <ref name="Borkotoky">PMID:36562937</ref>. The virus, [https://en.wikipedia.org/wiki/SARS-CoV-2 SARS-CoV-2], enters our bodies containing a <scene name='10/1077473/Rbd_only/2'>spike protein</scene> protruding from the viral membrane. The RBD on the end of the spike protein <scene name='10/1076049/Ace2andrbd/1'>binds to ACE2</scene> giving SARS-CoV-2 the ability to enter our host cells <ref name="Jackson">PMID:34611326</ref>. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies. Figure 1 demonstrates the path SARS-CoV-2 takes to get into our cells. In order to create an effective vaccine, the pathway between the spike protein and the RBD needed to be interrupted <ref name=”Zhu”>PMID:36682464</ref>.




Retrieved from "https://proteopedia.org/Engineered_Protein_Inhibitors_of_SARS-CoV-2_Entry"